POET Technologies: Production Milestones Clash with Legal Fallout as Shares Try to Find a Floor
Published on 07/22/2026 at 14:02 | Redaktion boerse-global.de
The story of POET Technologies right now is one of two competing narratives. On one side sits a photonics company with ambitious production targets, a major customer contract, and a cash pile that would make most small-cap tech firms envious. On the other is a stock that has shed roughly 60% of its value in just over two months, weighed down by a customer defection, a departing CFO, and class-action lawsuits that show no signs of fading.
Shares of the optical-engine specialist closed Tuesday at €7.28 in European trading, a gain of 11.15% on the day. The bounce came as the company provided fresh details on its manufacturing ramp-up in Malaysia, offering investors a reason to look past the legal overhang — at least for a session. The stock now trades about 6% above its 200-day moving average of €6.86, a technical level it recently reclaimed after weeks of violent swings.
That relative stability, however, masks a brutal stretch. On May 15, POET hit a 52-week high of €18.84. Since then, the shares have lost more than 60% of their value, with the bulk of the damage concentrated in a single session in late April when Marvell Technology canceled all outstanding orders. The trigger: allegations that CFO Thomas Mika had improperly shared confidential customer data.
The Malaysia Countdown
The company’s recovery thesis rests squarely on its ability to begin volume production of 800G optical modules in the third quarter of 2026. POET has partnered with Globetronics Manufacturing and NationGate Solution in Penang for assembly, testing, and light-source production. Management plans to increase manufacturing capacity more than tenfold, targeting one million units per month by the end of 2027.
Should investors sell immediately? Or is it worth buying POET Technologies?
To fund that expansion — which requires roughly $50 million in capital investment in the second half of this year — POET strengthened its balance sheet in May through a $400 million direct placement. The company now reports $429 million in cash and equivalents with minimal debt, though that figure must be weighed against the dilution the placement caused for existing shareholders.
The production ramp is backed by a supply agreement with Lumilens signed in May. The initial order is worth $50 million, with a framework that could reach $500 million over five years. POET also says it has ten active customer projects, each with an annual revenue potential of more than $100 million — a figure the company has used to pitch its long-term story to investors.
The Other Side of the Ledger
For all the production optimism, the near-term financials remain sobering. POET posted a net loss of $12.3 million in its most recent quarter, even as revenue grew more than 200% year over year in the first quarter of 2026. Over the past twelve months, the company has raised roughly $830 million in equity, a figure that underscores just how capital-intensive its path to scale has been.
The legal situation adds another layer of uncertainty. Law firms including Levi & Korsinsky and the Rosen Law Firm have filed class-action suits centered on alleged misrepresentations regarding tax classifications and the value destruction from the Marvell fallout. Mika announced his departure as CFO on May 15, with his exit expected before year-end, leaving the company to navigate both a leadership transition and a legal defense simultaneously.
Analyst Targets vs. Market Reality
Despite the share price collapse, sell-side analysts see significant upside. The consensus price target compiled by 24/7 Wall St. stands at $17.50, while the firm’s own base case for 2027 sits at $22.23. A stretch target of $25 is considered achievable if the Malaysia production ramp proceeds on schedule and the Lumilens business generates recurring revenue.
Those targets imply a recovery of 150% or more from current levels. But the market is clearly pricing in execution risk. The stock’s 30-day annualized volatility exceeds 102%, and its relative strength index of 42.5 sits in neutral territory — neither oversold nor overbought, but reflecting a market that has yet to pick a direction.
POET Technologies at a turning point? This analysis reveals what investors need to know now.
The broader sector backdrop offers some tailwinds. Applied Optoelectronics surged more than 15% on the same day POET rallied, while Astera Labs gained over 3%. The optics and transceiver space has benefited from sustained demand tied to AI data-center buildouts, a macro trend that supports POET’s product roadmap even if the company’s specific challenges remain company-specific.
What Comes Next
For POET, the next several months will determine whether the production story can overcome the legal and governance headwinds. The Malaysia facility is scheduled to begin 800G output in the third quarter, and the company’s hybrid Blazar laser platform is expected to enter large-scale deployment in 2028. Those are distant milestones for a stock that has lost nearly two-thirds of its value in two months.
The 200-day moving average at €6.86 has provided a technical floor for now. Whether that support holds will likely depend on execution updates from Penang — and on whether the market believes that the production ramp can deliver the revenue needed to offset the legal liabilities and dilution that have defined POET’s recent history.
Ad
POET Technologies Stock: New Analysis - 22 July
Fresh POET Technologies information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
